Webinar key points: AI Market Space Overview, How to Choose an AI Solution that Best Fits Your Clinical Practice, Challenges and Opportunities of AI Integration in Radiology Clinical Practice
Previous / On-Demand Webinars:
This will be an interactive Q/A style session discussing how early phase centralized image storage can help you secure funding.
Dr. Smalberg will define what a central reviewer is and discuss challenges and opportunities involved in interactions with imaging core labs and/or sponsors.
Learn about the fundamentals of Lugano Classification, data collection, and recent academia and industry recommendations on challenges of assessment.
Prostate cancer is one of the most common cancer types in men. With bone as a frequent metastatic site, response assessments for prostate cancer have additional considerations beyond RECIST 1.1.
iRECIST provides guidance for solid tumor response criteria in immunotherapy to accommodate possible pseudoprogression, which may occur in some subjects. In this presentation, MERIT will discuss the rules and principles of iRECIST, imaging endpoints, and special considerations for using iRECIST response criteria.
Does your oncology clinical trial have an imaging component? Are you new to working with imaging core labs? An imaging core lab can provide your team with resources, knowledge, and experience that can help make your study a success.
The Response Assessment in Neuro-Oncology (RANO) group provides various central nervous system-related tumor response criteria and guidance for assessments. In this webinar, MERIT will discuss the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for clinical trials.
RECIST 1.1 is the standard response criteria for solid tumors and has been a basis for adaptation and variation of other response criteria such as mRECIST, irRECIST, iRECIST, and so on. In this on-demand webinar recording, MERIT discusses the principles of RECIST 1.1, the information needed to collect imaging endpoints, and special considerations while using the RECIST 1.1 criteria.
Gain assurance with our proven track record providing reliable endpoint expertise to 12 of the top 20 global pharmaceutical companies
Reap the benefits of competitive pricing and shortened timelines resulting from efficiencies gained over decades of experience
Benefit from transparent communication and prompt access to in-house experts
Reduce clinical trial risk. Our experienced team delivers risk management by anticipating your study challenges
Increase your trial’s flexibility with our scalable solutions. We adapt quickly to your changing needs
Rely on MERIT consistently meeting customer and regulatory requirements as validated through our ISO 27001 and ISO 13485 certifications
Enhance the efficiency and accuracy of your imaging data collection and analysis with EXCELSIORTM, our cloud-based software solution
Simplify and streamline your pulmonary clinical trial process with CompleClinical®, MERIT’s innovative spirometry software application
Some companies tend to overpromise and underdeliver, which puts your study success at risk. If you’re looking for a clinical trial endpoint services provider that will value your partnership and make your study a priority, consider MERIT.